NeurAxis Highlights Pediatric Post-Concussion Clinical Study
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Concussion
VoxNeuro Raises $3.4M to Accelerate Scaling Its Brain Performance Software Across US Clinics
VoxNeuro’s technology addresses the increased demand for cognitive health assessments with a simplified and objective software solution Financing to support...
First-Ever BioMech Clinical Motion Lab Opens in Atlanta to Accelerate Traumatically Injured Patients’ Recovery using AI-driven Motion Science Technology in Clinic and at Home
BioMech, Atlanta's Independent Neurodiagnostic Clinic join forces to help patients and health care providers quantitatively measure and monitor function RICHMOND,...
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by...
Revolutionary Oxygen Treatment now available in Montreal at Les Cours Hyperbaric Center
Private Chamber Private Chamber Private Chamber (2) Private Chamber (2) Mono Private Chamber (Mom & Child) Mono Private Chamber (Mom...
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function...
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
New Study Reveals Effective Treatment for Children Suffering From Persistent Post-Concussion Syndrome
Study shows that hyperbaric oxygen therapy significantly improves symptoms, including memory, emotional and behavioral, and heals brain structure in cortical...
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II
Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
SyncThink Secures CE Mark for EYE-SYNC Digital Health Platform
Neurotechnology solution gains vital certification needed for EU expansion Palo Alto, CA – (August 10, 2022) – SyncThink, a next generation...
Odyssey Health, Inc. Launches New Corporate Website
Odyssey Health, Inc. Launches New Corporate Website $ODYY - Odyssey Health, Inc. - New Corporate WebsiteLas Vegas, NV, Aug. 04,...
Top Neurology and Chiropractic Clinicians Adopt EYE-SYNC
North Boulder Chiropractic and Restoration Neurology Onboard EYE-SYNC technology to improve patient care with objective data Palo Alto, CA—October 7,...